PHS
BCR

PFM Health Sciences’s CR Bard Inc. BCR Stock Holding History

PFM Health Sciences’s Portfolio BCR Stock Details BCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-75,570
Closed -$14.1M – 96
2015
Q3 		$14.1M Buy
+75,570
New +$14.3M 0.4% 52

Other funds holding BCR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FPP
Findlay Park Partners London, United Kingdom $7.41B AUM 26.32% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
YAM
Yacktman Asset Management Austin, Texas $8.09B AUM 19.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PFM Health Sciences's BCR Position: Q4 2015 in Review

PFM Health Sciences sold out of CR Bard Inc. (BCR) in Q4 2015, closing a stake of 75,570 shares — an estimated $14.1M sold.

PFM Health Sciences first reported a position in BCR in Q3 2015 and held it in 1 quarter. The position peaked at $14.1M in Q3 2015. 608 funds tracked by Wall St. Rank hold BCR as of Q4 2015.

  • PFM Health Sciences reported no remaining CR Bard Inc. position as of Q4 2015 after selling out during the quarter.
  • PFM Health Sciences sold 75,570 CR Bard Inc. shares in Q4 2015, an estimated $14.1M.
  • PFM Health Sciences first reported a position in CR Bard Inc. in Q3 2015 and held it in 1 quarter.
  • PFM Health Sciences's CR Bard Inc. position peaked at $14.1M in Q3 2015.
  • 608 funds tracked by Wall St. Rank held CR Bard Inc. as of Q4 2015.

Based on PFM Health Sciences's 13F filing for Q4 2015, filed 16 Feb 2016.